강직성 척추염 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Ankylosing spondylitis market size is anticipated to grow at an 8.2% CAGR between 2024 and 2032 driven by increasing awareness and diagnosis of the condition, coupled with advancements in treatment options. Innovations in imaging technologies and biomarker discoveries have facilitated earlier and more precise diagnoses, subsequently boosting the demand for specialized treatments and management strategies.

The market growth is also propelled by the rising prevalence of ankylosing spondylitis (AS) and an expanding patient demographic. Reports indicate that ankylosing spondylitis affects between 0.1% to 1.4% of the global population. As genetic and environmental factors drive the increasing incidence of AS, the demand for effective treatment solutions and management strategies intensifies. Moreover, heightened investments in R and D, alongside ongoing clinical trials for new therapeutic methods, are catalyzing the creation of innovative drugs and treatment modalities.

The industry is classified into treatment, route of administration, type, application, distribution channel, and region.

Based on treatment, the ankylosing spondylitis market size from the corticosteroids segment is poised to grow between 2024 and 2032 due to their proven efficacy in alleviating inflammation and managing AS-related symptoms. Corticosteroids not only offer swift relief from pain and swelling, enhancing patient mobility and overall quality of life but also play a pivotal role in controlling acute flare-ups and modulating immune responses, significantly boosting their demand.

AS market from the juvenile application segment is set to witness a significant CAGR from 2024 to 2032. This is driven by the rising acknowledgment and diagnosis of the disease in younger demographics, notably children and adolescents. Juveniles with early-onset AS often exhibit unique clinical features and face graver outcomes without timely intervention. This reality underscores the demand for specialized care and tailored treatment strategies that cater to the distinct needs of younger patients.

Asia Pacific ankylosing spondylitis industry is expected to accrue notable growth from 2024 to 2032. The growth is attributed to enhancements in healthcare infrastructure and a growing awareness of inflammatory diseases. The proliferation of advanced diagnostic facilities, coupled with specialized treatment centers, not only facilitates early diagnosis but also ensures effective management, bolstering the regional market expansion.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of ankylosing spondylitis
    • 3.2.1.2 Advancements in treatment options
    • 3.2.1.3 Rising healthcare expenditure
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with the medications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
• 5.3 Biologic therapies
  • 5.3.1 TNF inhibitors
  • 5.3.2 IL-17 inhibitors
• 5.4 JAK Inhibitors
• 5.5 Disease-modifying anti-rheumatic drugs (DMARDs)
• 5.6 Corticosteroids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Parenteral
• 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription drugs
• 7.3 OTC drugs

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Adults
• 8.3 Juveniles

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie, Inc.
• 11.2 Amgen, Inc.
• 11.3 Bayer AG
• 11.4 Eli Lilly and Company
• 11.5 Horizon Pharma
• 11.6 Janssen Biotech, Inc.
• 11.7 Merck and Co., Inc.
• 11.8 Novartis AG
• 11.9 PRIMUS PHARMACEUTICALS
• 11.10 Pfizer, Inc.
• 11.11 Sandoz Group AG
• 11.12 UCB, Inc.